1. Home
  2. MAIA vs WGRX Comparison

MAIA vs WGRX Comparison

Compare MAIA & WGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • WGRX
  • Stock Information
  • Founded
  • MAIA 2018
  • WGRX 2022
  • Country
  • MAIA United States
  • WGRX United States
  • Employees
  • MAIA N/A
  • WGRX N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • WGRX Other Pharmaceuticals
  • Sector
  • MAIA Health Care
  • WGRX Health Care
  • Exchange
  • MAIA Nasdaq
  • WGRX Nasdaq
  • Market Cap
  • MAIA 56.3M
  • WGRX 66.1M
  • IPO Year
  • MAIA 2022
  • WGRX 2025
  • Fundamental
  • Price
  • MAIA $1.70
  • WGRX $0.94
  • Analyst Decision
  • MAIA
  • WGRX
  • Analyst Count
  • MAIA 0
  • WGRX 0
  • Target Price
  • MAIA N/A
  • WGRX N/A
  • AVG Volume (30 Days)
  • MAIA 468.1K
  • WGRX 2.2M
  • Earning Date
  • MAIA 08-08-2025
  • WGRX 08-11-2025
  • Dividend Yield
  • MAIA N/A
  • WGRX N/A
  • EPS Growth
  • MAIA N/A
  • WGRX N/A
  • EPS
  • MAIA N/A
  • WGRX N/A
  • Revenue
  • MAIA N/A
  • WGRX $28,992,274.00
  • Revenue This Year
  • MAIA N/A
  • WGRX N/A
  • Revenue Next Year
  • MAIA N/A
  • WGRX N/A
  • P/E Ratio
  • MAIA N/A
  • WGRX N/A
  • Revenue Growth
  • MAIA N/A
  • WGRX N/A
  • 52 Week Low
  • MAIA $1.40
  • WGRX $0.75
  • 52 Week High
  • MAIA $3.74
  • WGRX $7.04
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 44.78
  • WGRX N/A
  • Support Level
  • MAIA $1.64
  • WGRX N/A
  • Resistance Level
  • MAIA $1.74
  • WGRX N/A
  • Average True Range (ATR)
  • MAIA 0.09
  • WGRX 0.00
  • MACD
  • MAIA -0.01
  • WGRX 0.00
  • Stochastic Oscillator
  • MAIA 11.76
  • WGRX 0.00

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About WGRX Wellgistics Health Inc. Common Stock

Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.

Share on Social Networks: